Gatifloxacin-associated corrected QT interval prolongation, Torsades de pointes, and ventricular fibrillation in patients with known risk factors

被引：41

作者：

Bertino, JS

Owens, RC

Carnes, TD

Iannini, PB

机构：

[1] Bassett Healthcare, Dept Pharm Serv, Div Clin Pharmacol, Clin Pharmacol Sect, Cooperstown, NY 13326 USA

[2] Bassett Healthcare, Dept Med, Div Clin Pharmacol, Cooperstown, NY 13326 USA

[3] Maine Med Ctr, Dept Clin Pharm, Portland, ME 04102 USA

[4] Maine Med Ctr, Dept Infect Dis, Portland, ME 04102 USA

[5] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA

[6] Danbury Hosp, Dept Med, Danbury, CT USA

来源：

CLINICAL INFECTIOUS DISEASES | 2002年 / 34卷 / 06期

关键词：

D O I：

10.1086/339075

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Drugs not commonly considered to be cardioactive agents have been reported to cause prolongation of the corrected QT interval with resultant torsades de pointes or ventricular fibrillation. We report 4 cases of gatifloxacin-associated cardiac toxicity in patients with known risk factors for this adverse event.

引用

页码：861 / 863

页数：3

共 14 条

[1] Quinolone-induced QT interval prolongation: a not-so-unexpected class effect [J].